CN102276607B - Imidazole [4,5-f]-1,10-phenanthroline derivatives as well as preparation method and application thereof - Google Patents
Imidazole [4,5-f]-1,10-phenanthroline derivatives as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102276607B CN102276607B CN201110143258A CN201110143258A CN102276607B CN 102276607 B CN102276607 B CN 102276607B CN 201110143258 A CN201110143258 A CN 201110143258A CN 201110143258 A CN201110143258 A CN 201110143258A CN 102276607 B CN102276607 B CN 102276607B
- Authority
- CN
- China
- Prior art keywords
- phenanthroline
- imidazoles
- derivative
- preparation
- imidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention provides imidazole [4,5-f]-1,10-phenanthroline derivatives as well as a preparation method and application thereof. The method comprises the following steps: oxidizing 1,10-phenanthroline into 1,10-phenanthroline-5,6-diketone; forming p-hydroxy benzimidazole[4,5-f]phenanthroline with p-hydroxybenzaldehyde in ammonium acetate and glacial acetic acid condition; and forming the imidazole [4,5-f]-1,10-phenanthroline derivatives with 2-dimethylaminoethyl chloride hydrochloride or 1-(2-ethyl) piperidine hydrochloride or 1-(2-ethyl) pyrroline hydrochloride in anhydrous degasified DMF (dimethylformamide) containing NaH. The prepared imidazole [4,5-f]-1,10-phenanthroline derivatives can selectively identify and stabilize telomere G-tetrable helix DNA (deoxyribonucleic acid) in the existence of excessive double helix DNA, and can effectively inhibit growth and propagation of HeLa and HepG2 cancer cells, and can be used for preparing antitumor medicaments.
Description
Technical field
The present invention relates to heterogeneous ring compound, be specifically related to a kind of imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is particularly as the purposes of antitumor drug.
Background technology
Telomeric dna is non-coding, height repeating sequences, and its structure is double-stranded except 3 ' end is the strand district by many G based compositions mostly.The Tumor-necrosis factor glycoproteins of the terminal DNA of people's telomere is 5 '-TTAGGG-3 ', and length is about 3-6kb, and its 3 '-end is the strand district of 100-200 base.Crystallography and NMR research shows, these multiple, be rich in G sequence at K
+Perhaps Na
+Exist down, can be folded into G-four chain body structures.
The major function of telomere is to prevent that in the chromosome duplication process disappearance of end of chromosome base pair and end end from merging.There is " end duplicates problem " in telomeric dna in human body cell, and archaeal dna polymerase is the end of duplicated chromosome fully.Therefore, along with cell fission, the base of telomeric dna shortens gradually, and last telomere length reaches threshold value, and it is dead then that cell gets into aging.Yet in cancer cells,, constantly increase base, stoped the shortening of telomere length, cause the cancer cells immortality at telomere 3 '-suspension strand through reverse transcriptase of telomere.What is interesting is that expression activity or activity are very not low in normal somatic cell for Telomerase, and activity is very high in the cancer cells of 85-90%.Because the substrate of Telomerase effect is a telomeric dna, stablizes the inhibition that four chain structures cause telomerase activation through small molecules, thereby has stoped the propagation of tumour cell.Therefore, G-four serobila DNA can impel the compound of formation of G-four serobilas or enhanced stability then possibly the potential therapeutic action arranged to cancer as the target spot of telomerase inhibitor.
Summary of the invention
The purpose of this invention is to provide a kind of imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline.
A kind of imidazoles provided by the invention [4,5-f] and 1, the 10-derivative of phenanthroline, its structural formula is following:
Imidazoles provided by the invention [4,5-f] and 1, the synthetic route of 10-derivative of phenanthroline is following:
Imidazoles provided by the invention [4,5-f] and 1, the preparation method of 10-derivative of phenanthroline may further comprise the steps:
(1) with 1,10-phenanthroline preparation 1,10-phenanthroline-5,6-diketone;
(2) with 1,10-phenanthroline-5,6-diketone and PARA HYDROXY BENZALDEHYDE prepare para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound;
(3) under the nitrogen protection, among the dry DMF that also outgases of sodium hydride 1: 4 in molar ratio～7 adding warps with para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound and mass concentration 25～50%, be heated to 110 ℃ of backflow 30-60min; Para hydroxybenzene and imidazoles [4 in molar ratio; 5-f] the phenanthroline compound: 2-dimethylamino monochloroethane hydrochloride=1: 2～5; 2-dimethylamino monochloroethane hydrochloride is dissolved in the DMF of dry degassing, then this solution is dropwise added in the above-mentioned reflux solution, 110 ℃ of reaction 72～96h; The reaction postcooling filters to room temperature, and filtrating boils off solvent and gets solid; This solid is dissolved in methyl alcohol, transfers pH=7.0 with hydrochloric acid and triethylamine, boil off solvent, the gained material separates with column chromatography, obtains imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline.
2-dimethylamino monochloroethane hydrochloride can use 1-(2-chloroethene alkyl) piperidine hydrochlorate or 1-(2-chloroethene alkyl) pyrroles's hydrochloride to replace in the step (3).
Research is illustrated in excessive duplex DNA and exists down, imidazoles [4,5-f] and 1, and the selectivity identification of 10-derivative of phenanthroline ability is also stablized four strands of helical dnas of telomere G-, and can suppress the growth and breeding of HeLa and HepG2 cell effectively, its IC
50Value is about 10 respectively
-6M and 10
-5M proves imidazoles [4,5-f] and 1, and the 10-derivative of phenanthroline can be used in the preparation antitumor drug.
Advantage compared with prior art of the present invention and effect:
The imidazoles that the present invention provides [4,5-f] and 1,10-derivative of phenanthroline compound method is simple, the imidazoles of preparation [4,5-f] and 1, the 10-derivative of phenanthroline can be in the presence of 10 times of excessive duplex DNAs, and selectivity identification is also stablized four strands of helical dnas of G-.The imidazoles [4,5-f] and 1 of the present invention's preparation, the 10-derivative of phenanthroline especially can suppress the growth and breeding of HeLa and HepG2 cell, IC effectively
50Value is about 10
-6With 10
-5M, the kill tumor cell is used for preparing anti-tumor medicine effectively.
Description of drawings
Fig. 1 is 1, and the 10-phenanthroline exists down, the FRET melting point curve of four strands of helical dnas of G-, and wherein: 0.2 μ M G-quadruplex DNA (▲) adds 2 μ M 1,10-phenanthroline (●).
Fig. 2 different concns imidazoles [4,5-f] and 1,10-derivative of phenanthroline exist down, the FRET melting point curve of four strands of helical dnas of G-, (A) embodiment 1 imidazoles [4,5-f] and 1,10-derivative of phenanthroline; (B) embodiment 2 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline; (C) embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline; Wherein: 0.2 μ MG-quadruplex DNA (▲); Add 1 μ M verivate (●); Add 2 μ M verivates (◆), add 3 μ M verivates
Figure 32 .0 μ M competition duplex DNA is to the influence of the FRET melting point curve of four strands of helical dnas of compound-G-, (A) embodiment 1 imidazoles [4,5-f] and 1,10-derivative of phenanthroline; (B) embodiment 2 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline; (C) embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline; Wherein: 0.2 μ MG-quadruplex DNA (▲), add 2.0 μ M verivates (◆), add 2.0 μ M verivates and 2.0 μ M duplex DNA (●).
Fig. 4 is hatched the imidazoles [4,5-f] and 1 of different concns after 72 hours, and the 10-derivative of phenanthroline is to the influence of HeLa cell viability, (A) embodiment 1 imidazoles [4,5-f] and 1,10-derivative of phenanthroline; (B) embodiment 2 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline; (C) embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline;
Fig. 5 is hatched the imidazoles [4,5-f] and 1 of different concns after 72 hours, and the 10-derivative of phenanthroline is to the influence of HepG2 cell viability, (A) embodiment 1 imidazoles [4,5-f] and 1,10-derivative of phenanthroline; (B) embodiment 2 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline; (C) embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline.
Following examples are in order to explanation the present invention
Embodiment 1: imidazoles [4,5-f] and 1, the preparation of 10-derivative of phenanthroline
(1) with (4g, 0.02mol) 1,10-phenanthroline and (4g; 0.03mol) KBr slowly adds in the 30mL vitriol oil of ice bath cooling and stirring respectively successively; The nitrosonitric acid of 15mL mass concentration 86%～97.5% is added in the above-mentioned solution, continue ice bath and stir 30min, reflux 5h afterwards.After the reaction liquid is poured in the 320g frozen water,, used 50mL * 8 dichloromethane extractions then with 10M NaOH neutralization.Extraction liquid is used anhydrous sodium sulfate drying, filters, and boils off solvent, obtains 1,10-phenanthroline-5, and the thick product of 6-diketone, recrystallizing methanol obtains 1,10-phenanthroline-5,6-diketone product;
(2) will (0.26g, 1.25mmol) 1,10-phenanthroline-5, the 6-diketone, (0.21g, 1.75mmol) PARA HYDROXY BENZALDEHYDE is with (1.92g, 25mmol) ammonium acetate adds in the 3.5mL glacial acetic acid, reflux 3h.Water washing and precipitating is filtered in reaction back dilute with water, ammoniacal liquor pH=6～7 that neutralize.Collecting precipitation after the vacuum-drying, is used the acetonitrile recrystallization, obtains para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound;
(3) under the nitrogen protection, will (0.20g, 0.7mmol) para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound with (0.13g, 3.4mmol) sodium hydride of mass concentration 25～50% be dissolved in through drying and the degassing 20mL DMF in, be heated to 110 ℃ of backflow 30min; (0.20g, 1.4mmol) 2-dimethylamino monochloroethane hydrochloride is dissolved in the 40mL of dry degassing DMF, this solution is dropwise added in the above-mentioned reflux solution 110 ℃ of reaction 72h.The reaction postcooling filters to room temperature, and filtrating boils off solvent and gets solid.This solid is dissolved in methyl alcohol, transfers pH=7.0 with hydrochloric acid and triethylamine, boil off solvent, the gained material separates with column chromatography, and developping agent is a methyl alcohol: chloroform: glacial acetic acid=1: 2: 0.02, obtain imidazoles [4,5-f] and 1, and the 10-derivative of phenanthroline, structural formula is:
Its physical constant and spectroscopic data are following:
Pale brown toner end, molecular formula: C
23H
21N
5O;
ESI(+)-MS(m/z)：384.58(100％)，[M+H]
+；789.33(100％)，[2M+Na]
+；
1H-NMR(300MHz，DMSO-d
6)：δ(ppm)9.01(m，4H)，8.29(d，J＝8.4Hz，2H)，7.82(m，2H)，7.14(d，J＝8.4Hz，2H)，4.16(m，2H)，2.67(m，2H)，2.25(m，6H)；
13C-NMR(75MHz，DMSO-d
6)：δ(ppm)160.0，151.9，148.0，143.5，130.6，128.5，123.8，122.4，115.2，66.4，58.1，46.0。
Embodiment 2: imidazoles [4,5-f] and 1, the preparation of 10-derivative of phenanthroline
(1), (2) process is with embodiment 1
(3) under the nitrogen protection, will (0.20g, 0.7mmol) para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound with (0.18g, 4.7mmol) sodium hydride of mass concentration 25～50% be dissolved in through drying and the degassing 20mL DMF in, be heated to 110 ℃ of backflow 60min; (0.52g, 2.8mmol) 1-(2-chloroethene alkyl) piperidine hydrochlorate is dissolved in the 50mL of dry degassing DMF, this solution is dropwise added in the above-mentioned reflux solution 110 ℃ of reaction 96h.The reaction postcooling filters to room temperature, and filtrating boils off solvent and gets solid.This solid is dissolved in methyl alcohol, transfers pH=7.0 with hydrochloric acid and triethylamine, boil off solvent, the gained material separates with column chromatography, and developping agent is a methyl alcohol: chloroform: glacial acetic acid=1: 4: 0.02, obtain imidazoles [4,5-f] and 1, and the 10-derivative of phenanthroline, structural formula is:
Its physical constant and spectroscopic data are following:
Pale brown toner end, molecular formula: C
26H
25N
5O;
ESI(+)-MS(m/z)：424.50(58％)，[M+H]
+；446.42(64％)，[M+Na]
+；869.33(100％)，[2M+Na]
+；
1H-NMR(300MHz，DMSO-d
6)：δ(ppm)9.12(m，2H)，9.01(m，2H)，8.38(m，2H)，?7.84(m，2H)，7.12(m，2H)，4.17(m，2H)，2.70(m，4H)，1.22-1.51(m，8H)；
13C-NMR(75MHz，DMSO-d
6)：δ(ppm)159.2，151.6，147.3，142.5，130.4，127.9，123.2，121.7，114.4，65.4，57.1，54.2，25.3，23.3。
Embodiment 3: imidazoles [4,5-f] and 1, the preparation of 10-derivative of phenanthroline
(1), (2) process is with embodiment 1
(3) under the nitrogen protection, will (0.20g, 0.7mmol) para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound with (0.13g, 3.4mmol) sodium hydride of mass concentration 25～50% be dissolved in through drying and the degassing 20mL DMF in, be heated to 110 ℃ of backflow 40min; (0.60g, 3.5mmol) 1-(2-chloroethene alkyl) pyrroles's hydrochloride is dissolved in the 50mL of dry degassing DMF, this solution is dropwise added in the above-mentioned reflux solution 110 ℃ of reaction 82h.The reaction postcooling filters to room temperature, and filtrating boils off solvent and gets solid.This solid is dissolved in methyl alcohol, transfers pH=7.0 with hydrochloric acid and triethylamine, boil off solvent, the gained material separates with column chromatography, and developping agent is a methyl alcohol: chloroform: glacial acetic acid=1: 3: 0.02, obtain imidazoles [4,5-f] and 1, and the 10-derivative of phenanthroline, structural formula is:
Its physical constant and spectroscopic data are following:
Pale brown toner end, molecular formula: C
25H
23N
5O;
ESI(+)-MS(m/z)：410.42(100％)，[M+H]
+；
1H-NMR(300MHz，DMSO-d
6)：δ(ppm)9.05(m，4H)，8.38(d，J＝8.4Hz，2H)，7.84(m，2H)，7.13(d，J＝7.8Hz，2H)，4.17(t，J＝5.7Hz，2H)，2.83(t，J＝5.7Hz，2H)，2.72(m，4H)，1.70(m，4H)；
13C-NMR(75MHz，DMSO-d
6)：δ(ppm)161.9，153.4，149.5，142.5，130.6，126.4，124.6，121.7，117.2，68.9，56.4，31.6，25.5。
Embodiment 4 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to the stabilizing power and the Study on Selectivity of four strands of helical dnas of people's telomere G-
We use FRET-fusing point (FRET-melting) experiment, study imidazoles [4,5-f] and 1, and the 10-derivative of phenanthroline is to the identification and the stabilizing power of four strands of helical dnas of G-.For imidazoles [4,5-f] and 1 better are described, the 10-derivative of phenanthroline is to the identification and the stabilization of four strands of helical dnas of G-simultaneously, and we are with 1, and the 10-phenanthroline compares FRET-fusing point experiment of four strands of helical dnas of G-.Used dna sequence dna is 5 '-FAM-GGG (TTAGGG) 3-TAMRA-3 ', i.e. 5 ' and 3 ' terminal people's telomeric sequence 5 '-GGG (TTAGGG) 3-3 ' that uses FAM and TAMRA mark respectively.Buffer system is: 10mM natrium cacodylicum (pH 7.4), 100mM NaCl.The result is shown in Fig. 1, Fig. 2 and table 1.Table 1 has been listed at 2 μ M 1,10-phenanthroline and different imidazoles thereof [4,5-f] and 1; Under the 10-derivative of phenanthroline concentration, 1,10-phenanthroline and imidazoles [4 thereof; 5-f] and 1, the 10-derivative of phenanthroline makes melting temperature increased value (the Δ T of four strands of helical dnas of G-
m).The result shows that with 1, the 10-phenanthroline is compared, and imidazoles [4,5-f] and 1,10-derivative of phenanthroline can effectively improve the stability of four strands of helical dnas of the terminal G-of people's telomere.
1 of table 12 μ M concentration, 10-phenanthroline and different concns imidazoles thereof [4,5-f] and 1, the 10-derivative of phenanthroline is to the influence of four strands of helical dna melting temperatures of G-
In order to study imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to the selectivity of four strands of relative duplex DNAs of spiral of G-, and we have carried out competition FRET-fusing point (FRET-melting) experiment.In people's telomeric dna experimental system of the above-mentioned mark of 0.2 μ M, adding does not have the chromophoric group mark and excessive 10 times duplex DNA (2.0 μ M); Observe the adding of excessive greatly duplex DNA; 2 μ M imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to four gangs of spiral T of G-
mThe influence of value.Wherein, the sequence of competitor dna is 5 '-CAATCGGATCGAATTCGATCCGATTG-3 ', in solution, forms duplex DNA from complementation.The result is shown in Fig. 2 and table 2.The result shows, under the condition that 10 times of excessive duplexs exist, and imidazoles [4; 5-f] and 1; The 10-derivative of phenanthroline is influenced hardly or influence is very little to the stability of four strands of helical dnas of G-, and imidazoles [4,5-f] also 1 be described; Four strands of helical dnas of the 10-derivative of phenanthroline selectively targeted G-of ability, and can effective as selective identification and four strands of helical dnas of stabilizes telomere G-.
There is imidazoles [4,5-f] and 1 down in table 2 competition duplex DNA, and the 10-derivative of phenanthroline is to the influence of four strands of helical dna melting temperatures of G-
Embodiment 5 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to the research of tumor cell activity
In order to study imidazoles [4; 5-f] and 1; The 10-derivative of phenanthroline is to the toxicity of tumour cell, and we have tested imidazoles [4,5-f] and 1 with mtt assay; The 10-derivative of phenanthroline is to born of the same parents' toxic action of human cervical carcinoma cell (HeLa cell) and human liver cancer cell (HepG2 cell), and the result is respectively like Fig. 4 and shown in Figure 5.Find imidazoles [4,5-f] and 1,10-derivative of phenanthroline and HeLa co-culture of cells are after 72 hours; Embodiment 1 imidazoles [4,5-f] and 1,10-derivative of phenanthroline, embodiment 2 imidazoles [4; 5-f] and 1; 10-derivative of phenanthroline and embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to the IC of HeLa cell
50Value is respectively 1.0,0.6 and 0.8 μ M; Imidazoles [4,5-f] and 1,10-derivative of phenanthroline and HepG2 co-culture of cells are after 72 hours; Embodiment 1 imidazoles [4,5-f] and 1,10-derivative of phenanthroline, embodiment 2 imidazoles [4; 5-f] and 1; 10-derivative of phenanthroline and embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to the IC of HepG2 cell
50Value is respectively 8.9,8.5 and 18.9 μ M.
More than research is illustrated in ten times of duplex DNAs existence down, imidazoles [4,5-f] and 1, and the 10-derivative of phenanthroline can selectivity identification also be stablized four strands of helical dnas of telomere G-; And can suppress the growth and breeding of HeLa and HepG2 cell effectively, cultivate embodiment 1 imidazoles [4,5-f] and 1 after 72 hours altogether; The 10-derivative of phenanthroline, embodiment 2 imidazoles [4,5-f] and 1; 10-derivative of phenanthroline and embodiment 3 imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is to the IC of HeLa cell
50Value is respectively 1.0,0.6 and 0.8 μ M, to the IC of HepG2 cell
50Value is respectively 8.9,8.5 and 18.9 μ M, can be used for preparing anti-tumor medicine.
Claims (4)
1. an imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline is characterized in that, structural formula is:
2. a kind of imidazoles according to claim 1 [4,5-f] and 1, the preparation method of 10-derivative of phenanthroline is characterized in that may further comprise the steps:
(1) with 1,10-phenanthroline preparation 1,10-phenanthroline-5,6-diketone;
(2) with 1,10-phenanthroline-5,6-diketone and PARA HYDROXY BENZALDEHYDE prepare para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound;
(3) under the nitrogen protection, among the dry DMF that also outgases of sodium hydride 1: 4 in molar ratio～7 adding warps with para hydroxybenzene and imidazoles [4,5-f] phenanthroline compound and mass concentration 25～50%, be heated to 110 ℃ of backflow 30-60min; Para hydroxybenzene and imidazoles [4 in molar ratio; 5-f] phenanthroline compound: 1-(2-chloroethene alkyl) piperidine hydrochlorate=1: 2～5; 1-(2-chloroethene alkyl) piperidine hydrochlorate is dissolved in the DMF of dry degassing; Then this solution is dropwise added in the above-mentioned reflux solution 110 ℃ of reaction 72～96h; The reaction postcooling filters to room temperature, and filtrating boils off solvent and gets solid; This solid is dissolved in methyl alcohol, transfers pH=7.0 with hydrochloric acid and triethylamine, boil off solvent, the gained material separates with column chromatography, obtains imidazoles [4,5-f] and 1, the 10-derivative of phenanthroline.
3. a kind of imidazoles according to claim 2 [4,5-f] and 1, the preparation method of 10-derivative of phenanthroline is characterized in that 1-(the 2-chloroethene alkyl) piperidine hydrochlorate in the said step (3) substitutes with 1-(2-chloroethene alkyl) pyrrolidine hydrochloride.
4. a kind of imidazoles according to claim 1 [4,5-f] and 1, the application of 10-derivative of phenanthroline in the preparation antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110143258A CN102276607B (en) | 2011-05-26 | 2011-05-26 | Imidazole [4,5-f]-1,10-phenanthroline derivatives as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110143258A CN102276607B (en) | 2011-05-26 | 2011-05-26 | Imidazole [4,5-f]-1,10-phenanthroline derivatives as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102276607A CN102276607A (en) | 2011-12-14 |
| CN102276607B true CN102276607B (en) | 2012-10-17 |
Family
ID=45102391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110143258A Expired - Fee Related CN102276607B (en) | 2011-05-26 | 2011-05-26 | Imidazole [4,5-f]-1,10-phenanthroline derivatives as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102276607B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103193801B (en) * | 2013-04-02 | 2015-11-18 | 福州大学 | A kind of copper (II) title complex and application thereof |
| CN103497190B (en) * | 2013-09-30 | 2016-03-02 | 京东方科技集团股份有限公司 | Derivative of imidazoles [4,5-f] [1,10] phenanthroline and its preparation method and application |
| CN106010502B (en) * | 2015-11-24 | 2019-03-01 | 河北科技大学 | A kind of preparation method of the rare earth mesoporous hybridisation luminescent material with fluorine ion sensing performance |
| CN106317096B (en) * | 2016-08-19 | 2019-05-28 | 华南师范大学 | A kind of Phen and imidazole type rare earth coordination molecule base probe and its preparation method and application |
| CN106565713B (en) * | 2016-10-10 | 2019-01-15 | 浙江工业大学 | 2 '-pyrazoles -1H- imidazoles [4,5-f] [1,10] Féraud quinoline derivants and its preparation method and application |
| CN108329317B (en) * | 2018-04-10 | 2020-03-10 | 重庆文理学院 | Phenanthroline derivative and preparation method and application thereof |
| CN114671870B (en) * | 2022-03-18 | 2023-03-31 | 广州鲁比生物科技有限公司 | Cinnamyl aldehyde derivative and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101701024A (en) * | 2009-10-30 | 2010-05-05 | 暨南大学 | Ruthenium complex, preparation method thereof and application thereof |
| CN101717413A (en) * | 2007-09-27 | 2010-06-02 | 广东药学院 | Chiral ruthenium coordination compound and application of same as anti-tumour medicine |
| CN101735217A (en) * | 2009-12-15 | 2010-06-16 | 广东药学院 | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug |
| WO2010102393A1 (en) * | 2009-03-12 | 2010-09-16 | Lorus Therapeutics Inc. | 2-indolyl imidazo [4,5-d]phenanthroline derivatives and their use to inhibit angiogenesis |
| CN101967144A (en) * | 2010-09-03 | 2011-02-09 | 山西大学 | Phenanthroline derivative and preparation method and application thereof |
-
2011
- 2011-05-26 CN CN201110143258A patent/CN102276607B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101717413A (en) * | 2007-09-27 | 2010-06-02 | 广东药学院 | Chiral ruthenium coordination compound and application of same as anti-tumour medicine |
| WO2010102393A1 (en) * | 2009-03-12 | 2010-09-16 | Lorus Therapeutics Inc. | 2-indolyl imidazo [4,5-d]phenanthroline derivatives and their use to inhibit angiogenesis |
| CN101701024A (en) * | 2009-10-30 | 2010-05-05 | 暨南大学 | Ruthenium complex, preparation method thereof and application thereof |
| CN101735217A (en) * | 2009-12-15 | 2010-06-16 | 广东药学院 | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug |
| CN101967144A (en) * | 2010-09-03 | 2011-02-09 | 山西大学 | Phenanthroline derivative and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 李襄宏等.基于1 10-邻菲罗啉衍生物的两亲性钌配合物的合成及其光电转化性质.《中南民族大学学报(自然科学版)》.2009 |
| 李襄宏等.基于1,10-邻菲罗啉衍生物的两亲性钌配合物的合成及其光电转化性质.《中南民族大学学报(自然科学版)》.2009,(第03期), * |
| 陈华梅等.2-(2,4-二溴苯酚基)-1H-咪唑[4,5-f][1,10]邻菲罗啉的合成及其对阴离子的识别性能.《合成化学》.2010,(第05期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102276607A (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102276607B (en) | Imidazole [4,5-f]-1,10-phenanthroline derivatives as well as preparation method and application thereof | |
| GB2587457A (en) | Methods and compositions for modulating splicing | |
| JP2021091722A (en) | Aziridine-containing DNA alkylating agent | |
| CN104803925A (en) | 2,4,5-trisubstituted pyrimidine compounds taking FGFRs (fibroblast growth factor receptors) as targets as well as preparation methods and application of 2,4,5-trisubstituted pyrimidine compounds | |
| US20190112276A1 (en) | Pu.1 inhibitors | |
| CN106432247A (en) | Pyrimidotriazole compounds containing hydrazone bonds as well as preparation method and application of pyrimidotriazole compounds | |
| CN105732468A (en) | N'-(2-(1H-indole-3-yl)acetyl)arylhydrazide compound and preparation method and application thereof | |
| CN104529895B (en) | Synthetic method of replacing nitrogen-containing heterocyclic compound | |
| US20220259222A1 (en) | Mk2 inhibitors, the synthesis thereof, and intermediates thereto | |
| CN103113300A (en) | Preparation method and application of compound with antitumor activity | |
| CN105481869A (en) | Pyrano [3,2-a] phenazine derivative, preparation method and application thereof | |
| CN111454254B (en) | Preparation and application of benzimidazole derivative with fluorine-containing substituent | |
| CN109942499B (en) | Quinazoline derivative and preparation method and application thereof | |
| US20190330197A1 (en) | Substituted naphthalene diimides and their use | |
| CN105272921A (en) | Method for preparing Ceritinib and intermediate compound of Ceritinib | |
| CN104447436A (en) | Sulfonyl hydrazone derivative, preparation method as well as anti-free radical or anti-tumor activity application of sulfonyl hydrazone derivative | |
| CN111057004B (en) | N-o-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof | |
| CN101967144A (en) | Phenanthroline derivative and preparation method and application thereof | |
| CN108912059B (en) | Synthetic method of nitrogenous heterocyclic inflammation inhibiting compound | |
| CN110041349A (en) | One kind dihydropyrimidine derivatives containing spiral shell and its preparation method and application | |
| CN115160279B (en) | Benzopyrone compounds, pharmaceutical compositions and uses | |
| CN103626776B (en) | Pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, preparation methods of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives, and application of pyrazolo[1,5-alpha] pyrimidine nitrogen mustard derivatives in oncotherapy | |
| CN114920695B (en) | Quinazoline derivative, preparation method thereof, pharmaceutical composition and application | |
| CN112438977B (en) | Myricetin derivative containing benzimidazole, preparation method and application | |
| RU2527459C1 (en) | Novel heteroarene anthracenedione-based g-quadruplex ligands inhibiting tumour cell growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121017 Termination date: 20150526 |
|
| EXPY | Termination of patent right or utility model |